Full history for every metric is available with a Kvantra account
Clearside Biomedical, Inc. (CLSD)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 2 | 8 | 30 | 1 | 8 | 2 | 3 |
| Operating profit | $m | -29 | -23 | |||||
| Net profit | $m | -31 | -18 | 0 | -33 | -32 | -34 | -26 |
| EPS reported | $ | -7.05 | -5.10 | |||||
| Operating cashflow per share | $ | -5.02 | -1.95 | |||||
| Capex per share | $ | 0.20 | 0.00 | |||||
| FCF per share | $ | -5.22 | -1.95 | |||||
| Free cash flow | $m | -26 | -22 | |||||
| Net debt | $m | 32 | -7 | |||||
| Book value equity | $m | -39 | -54 | |||||
| Book value per share | $ | -7.90 | -10.31 | |||||
| Number of shares | m | 4.92 | 5.23 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -1.80 | -0.04 | |||||
| P/S LTM | x | 42.14 | 0.64 | |||||
| P/FCF LTM | x | -2.73 | -0.10 | |||||
| EV/EBITDA LTM | x | -4.21 | 0.32 | |||||
| EV/Sales LTM | x | 61.64 | -1.40 | |||||
| Earnings Yield LTM | % | -49.00% | -487.76% | |||||
| FCF Yield | % | -36.62% | -1012.9% | |||||
| Quality | ||||||||
| ROE | % | 88.41% | 20.39% | |||||
| ROIC | % | -139.48% | -114.62% | |||||
| Operating margin | % | -1735.7% | -1530.7% | |||||
| Gross margin | % | 91.05% | 87.88% | |||||
| FCF/Sales | % | -1543.0% | -1473.2% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -79.77% | -56.78% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.49 | -48.74 | |||||
| Net Debt/EBITDA | x | -1.33 | 1.28 | |||||
| EBIT/Net interest | x | -2.95 | -1.99 | |||||
| Net debt/market cap | % | 45.81% | -316.92% | |||||
| Net debt/Equity | x | -0.83 | 0.13 | |||||
| Gross debt/equity | x | -1.35 | -0.01 | |||||
Company overview
Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to pioneering novel drug delivery methods to the posterior segment of the eye via the suprachoroidal space. Its commercial product, XIPERE, is a triamcinolone acetonide suprachoroidal injectable suspension designed for treating uveitis macular edema. The company's development pipeline also features CLS-AX, an axitinib injectable suspension administered into the suprachoroidal space, which is currently undergoing Phase 1/2a clinical trials. Additionally, they are advancing CLS-301, an integrin inhibitor suspension aimed at addressing diabetic macular edema and macular degeneration. Clearside maintains strategic partnerships with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Established in 2011, Clearside Biomedical, Inc. is headquartered in Alpharetta, Georgia.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Clearside Biomedical, Inc. (CLSD)
Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to pioneering novel drug delivery methods to the posterior segment of the eye via the suprachoroidal space. Its commercial product, XIPERE, is a triamcinolone acetonide suprachoroidal injectable suspension designed for treating uveitis macular edema. The company's development pipeline also features CLS-AX, an axitinib injectable suspension administered into the suprachoroidal space, which is currently undergoing Phase 1/2a clinical trials. Additionally, they are advancing CLS-301, an integrin inhibitor suspension aimed at addressing diabetic macular edema and macular degeneration. Clearside maintains strategic partnerships with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Established in 2011, Clearside Biomedical, Inc. is headquartered in Alpharetta, Georgia.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free